SAGE Therapeutics (SAGE) Tops Q4 EPS by 36c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LVS
9. LRCX
10. MRK

Go back to SAGE Therapeutics (SAGE) Tops Q4 EPS by 36c, Revenues Miss

Sage Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Highlights Pipeline and Business Progress

February 27, 2020 6:30 AM EST

ZULRESSO (brexanolone) CIV injection net revenues of $2M and $4M for fourth quarter and full year 2019, respectively

Evaluating path forward for the zuranolone (SAGE-217) Landscape Program

Continued expansion of Neurology and Neuropsychiatry franchises with planned initiation of additional SAGE-324 and SAGE-718 studies in 2020

Conference call today at 8:00 a.m. EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Today, Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of... More